#United States #New York #Class Action #Levi & Korsinsky #Organon

Levi & Korsinsky Alerts Shareholders of Organon Class Action Lawsuit

Levi & Korsinsky, LLP has recently taken significant steps to notify investors in Organon & Co. (ticker: OGN) about a class action securities lawsuit that is currently in progress. The lawsuit centers around allegations of securities fraud that occurred between October 31, 2024, and April 30, 2025. For those affected by these events, the firm has emphasized the urgent need to act quickly as the deadline for filing claims is approaching.

Overview of the Case

The lawsuit alleges that the executives of Organon intentionally misled investors by providing overly positive statements while simultaneously concealing crucial adverse information. This misleading information primarily related to the company's financial priorities, particularly focusing on their capital allocation strategy. Most notably, after the company acquired Dermavant, Organon had significantly prioritized debt reduction, ultimately resulting in a dramatic 70% cut in its quarterly dividends. This reduction came as a significant shock to investors, leading to a severe drop in share value.

Following the release of this information, Organon's stock plummeted from $12.93 per share to $9.45 per share in a single trading session—a staggering decline of more than 27%. This incident has left many shareholders reeling and dissatisfied, prompting the initiation of class action proceedings.

Investors' Rights

For shareholders affected by this sharp decline in stock value, Levi & Korsinsky is committed to helping these individuals navigate the complexities of securities litigation. If you experienced financial losses during the specified period, you might still have time to request the court to appoint you as a lead plaintiff. However, it's important to note that participation in any potential recovery does not necessitate being a lead plaintiff. The critical deadline for filing your request is set for July 22, 2025.

No Financial Risk for Participants

Levi & Korsinsky has assured affected investors that there will be no out-of-pocket expenses or fees for those who choose to participate in the class action lawsuit. This means that potential claimants can seek compensation for their losses without the financial burden often associated with legal proceedings.

Why Choose Levi & Korsinsky?

With over two decades of experience in the field, Levi & Korsinsky has established itself as a powerhouse in securities litigation. They have successfully recovered hundreds of millions of dollars for aggrieved shareholders and have developed a strong reputation for winning challenging cases. The firm consists of a dedicated team of over 70 professionals, making them more than equipped to handle complex litigation matters.

Year after year, Levi & Korsinsky has been recognized by ISS Securities Class Action Services as one of the top securities litigation firms in the United States, adding to their credentials as a trustworthy advocate for investor rights.

Contact Information

For further inquiries or to discuss your potential claim, investors can directly reach out to Joseph E. Levi, Esq., at Levi & Korsinsky via email or phone:

• - Email: [email protected]
• - Phone: (212) 363-7500

This class action offers a critical opportunity for investors who feel wronged by Organon's conduct during the outlined period. As the deadline approaches, potential plaintiffs are encouraged to act promptly to ensure their rights are protected.